These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
17. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody. Dahan K; Johannet C; Esteve E; Plaisier E; Debiec H; Ronco P Kidney Int; 2019 Jan; 95(1):233-234. PubMed ID: 30606419 [No Abstract] [Full Text] [Related]
18. Plasmapheresis combined with rituximab for refractory idiopathic membranous nephropathy. Wen M; Küchle C; Sarkar O; Renders L; Heemann U; Schmaderer C Int Urol Nephrol; 2014 Apr; 46(4):847-8. PubMed ID: 24585365 [No Abstract] [Full Text] [Related]
19. The Efficacy of Rituximab in the Treatment of Membranous Nephropathy. Maharjan R; Wang JW; Shrestha IK J Nepal Health Res Counc; 2021 Jan; 18(4):580-587. PubMed ID: 33510493 [TBL] [Abstract][Full Text] [Related]
20. Rituximab for idiopathic membranous nephropathy. Remuzzi G; Chiurchiu C; Abbate M; Brusegan V; Bontempelli M; Ruggenenti P Lancet; 2002 Sep; 360(9337):923-4. PubMed ID: 12354476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]